Details
 

October 6-13, 2020

Hospitals: Clinical Overview and Use of Quzyttir

Hosted by TerSera

A Virtual Event - Multiple Broadcast Times

Quzyttir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute urticaria in adults and children 6 months of age and older. It is the first and only 2nd generation IV histamine‐1 (H1) receptor antagonist indicated for the treatment of acute urticaria. Please see the Indication and Important Safety Information below and click here for full Prescribing Information.

You are invited to register for a TerSera Therapeutics’ educational webinar. Presentations will be held throughout October.

The webcasts will provide an overview of Quzyttir (cetirizine HCl injection) 10mg/mL and discussion will include:

  • FDA approved language
  • Data from Phase 3 head‐to‐head trial vs. IV diphenhydramine
  • Use of Quzyttir in clinical practice

QUZYTTIR® (cetirizine HCl injection), for intravenous use

INDICATIONS AND USAGE

QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older.

imitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function.

IMPORTANT SAFETY INFORMATION

Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine.

Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur.

Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis. The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis, and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting.

For more information, please see the accompanying full Prescribing Information for QUZYTTIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.

Quzyttir® is a registered trademark of TerSera Therapeutics LLC or its affiliates.

©2020 TerSera Therapeutics LLC. All rights reserved. QYR‐P‐0060 (9/2020)

Printer-Friendly Version


2020-10-06 2020-10-13 America/Detroit Hospitals: Clinical Overview and Use of Quzyttir Quzyttir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute urticaria in adults and children 6 months of age and older. It is the first and only 2nd generation IV histamine‐1 (H1) receptor antagonist indicated for the treatment of acute urticaria. Please see the Indication and Important Safety Information below and click here for full Prescribing Information. You are invited to register for a TerSera Therapeutics’ educational webinar. Presentations will be held throughout October. The webcasts will provide an overview of Quzyttir (cetirizine HCl injection) 10mg/mL and discussion will include: FDA approved language Data from Phase 3 head‐to‐head trial vs. IV diphenhydramine Use of Quzyttir in clinical practice QUZYTTIR® (cetirizine HCl injection), for intravenous use INDICATIONS AND USAGE QUZYTTIR is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. imitations of Use: QUZYTTIR is not recommended in pediatric patients <6 years of age with impaired renal or hepatic function. IMPORTANT SAFETY INFORMATION Contraindications: Known hypersensitivity to QUZYTTIR or any of its ingredients, to levocetirizine, or hydroxyzine. Warnings and Precautions: The occurrence of somnolence/sedation has been reported in some patients. Advise patients to exercise due caution when driving or operating potentially dangerous machinery. Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. Adverse Reactions: The most common adverse reactions (incidence <1%) with QUZYTTIR are dysgeusia, headache, paresthesia, presyncope, dyspepsia, feeling hot, and hyperhidrosis. The most common adverse reactions (incidence ≥2%) with chronic dosing of oral cetirizine hydrochloride in adults are somnolence, fatigue, dry mouth, pharyngitis, and dizziness. Adverse reactions observed in pediatric patients with chronic use of oral cetirizine hydrochloride are headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting. For more information, please see the accompanying full Prescribing Information for QUZYTTIR. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088. Quzyttir® is a registered trademark of TerSera Therapeutics LLC or its affiliates. ©2020 TerSera Therapeutics LLC. All rights reserved. QYR‐P‐0060 (9/2020) A Virtual Event - Multiple Broadcast Times